Cardiovascular hazard of selective COX-2 inhibitors: Myth or reality?

Expert Opinion on Drug Safety

Volumn 1, Issue 1, 2002, Pages 45-52

  Chiolero, Arnaud ^a   Burnier, Michel ^a   Maillard, Marc P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

aspirin; cardiovascular; selective COX 2 inhibitors; sodium retention

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; EXPERT WITNESS; HUMAN; MORTALITY; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; ASPIRIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; EXPERT TESTIMONY; HUMANS; LACTONES; OSTEOARTHRITIS; PYRAZOLES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 0043237940     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.1.45     Document Type: Review

References (50)

1. AWTRY EH, LOSCALZO J: Aspirin. Circulation (2000) 101(10):1206-1218. (Pubitemid 30146625)
2. HAWKEY CJ: COX-2 inhibitors. Lancet (1999) 353(9149):307-314. (Pubitemid 29089366)
3. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340(24):1888-1899. (Pubitemid 29272670)
4. Erratum, N. Engl. J. Med. (1999) 341(7):548.
5. FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345(6):433-442. (Pubitemid 32747607)
6. PETERSEN M: Doubts are raised on the safety of 2 popular arthritis drugs. New York Times, Business/Financial Desk (2001) May 22:1.
7. KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384(6610):644-648.
8. FELDMAN M, MCMAHON AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Int. Med. (2000) 132(2):134-143. (Pubitemid 30044181)
9. WIGHT NJ, GOTTESDIENER K, GARLICK NM et al.: Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology (2001) 120(4):867-873. (Pubitemid 32193184)
10. CATELLA-LAWSON FC, CROFFORD LJ: Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. (2001) 110(3A):28S-32S. (Pubitemid 32155400)
11. KOMERS R, ANDERSON S, EPSTEIN M: Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am. J. Kid. Dis. (2001) 38(6):1145-1157. (Pubitemid 34193098)
12. CAMACHO M, LOPEZ-BELMONTE J, VILA L: Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ. Res. (1998) 83(4):353-365. (Pubitemid 28389965)
13. OKAHARA K, SUN B, KAMBAYASHI J: Upregulation of prostacyclin synthesisrelated gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. (1998) 18(12):1922-1926. (Pubitemid 28565755)
14. CATELLA-LAWSON F, MCADAM B, MORRISON BW et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, haemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. (1999) 289(2):735-741. (Pubitemid 29191226)
15. FUNG HB, KIRSCHENBAUM HL: Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin. Ther. (1999) 21(7):1131-1157. (Pubitemid 29380470)
16. TANG C, SHOU M, MEI Q, RUSHMORE TH, RODRIGUES AD: Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. (2000) 293(2):453-459. (Pubitemid 30244094)
17. BOMBARDIER C, LAINE L, REICIN A et al.: For the VIOGO study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. (2000) 343(21):1520-1528.
18. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised controlled trial. JAMA (2000) 284(10):1247-1255.
19. KOMHOFF M, GRONE HJ, KLEIN T, SEYBERTH HW, NUSING RM: Localisation of cyclooxygenase-1 and-2 in adult and foetal human kidney: implication for renal function. Am. J. Physiol. (1997) 272(4 Pt 2):F460-F468.
20. YANG T, SINGH I, PHAM H et al.: Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am. J. Physiol. (1998) 274(3 Pt 2):F481-F489.
21. BRATER DC, HARRIS RC, REDFERN JS, GERTZ BJ: Renal effects of COX-2 selective inhibitors. Am. J. Nephrol. (2001) 21(1):1-15. (Pubitemid 32238607)
22. HARRIS RC, BREYER MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal Physiol. (2001) 281(1):F1-F11.
23. ROSSAT J, MAILLARD M, NUSSBERGER J, BRUNNER HR, BURNIER M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. (1999) 66(1):76-84. (Pubitemid 29350448)
24. WHELTON A, MAURATH CJ, VERBURG KM, GEIS GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. J. Ther. (2000) 7(3):159-175.
25. WHITE WB, FAICH G, WHELTON A et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol. (2002) 89(4):425-430. (Pubitemid 34142518)
26. WHELTON A, FORT JG, PUMA JA, NORMANDIN D, BELLO AE, VERBURG KM: Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomised, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. (2001) 8(2):85-95. (Pubitemid 33753522)
27. PAGE J, HENRY D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch. Intern. Med. (2000) 160(6):777-784. (Pubitemid 30165238)
28. JOHNSON AG, NGUYEN TV, DAY RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann. Int. Med. (1994) 121(4):289-300.
29. WHELTON A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implication. Am. J. Med. (1999) 106(5B):13S-24S. (Pubitemid 29268660)
30. HAMBERG M, SVENSSON J, SAMUELSSON B: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA (1975) 72(8):2994-2998.
31. FITZGERALD GA, SMITH B, PEDERSON AK, RASH AR: Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. (1984) 310(17):1065-1068. (Pubitemid 14131497)
32. BING RJ, LOMNICKA M: Why do cyclooxygenase-2 inhibitors cause cardiovascular events? J. Am. Coll. Cardiol. (2002) 39:521-522. (Pubitemid 34117511)
33. SANMUGANATHAN PS, GHAHRAMANI P, JACKSON PR, WALLIS EJ, RAMSAY LE: Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 85(3):365-271.
34. LEESE PT, HUBBARD RC, KARIM A, ISAKSON PC, YU SS, STEVEN GEIS G: Effects of celecoxib, a novel cyclooxgenase-2 inhibitor, on platelet function in healthy adults: a randomised, controlled trial. J. Clin. Pharmacol. (2000) 40(2):134-132.
35. MCADAM BF, CATELLA-LAWSON F, MARDINI IA, KAPOOR S, LAWSON JA, FITZGERALD GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA (1999) 96(1):272-277. (Pubitemid 29036089)
36. HENNAN JK, HUANG J, BARRETT TD et al.: Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation (2001) 104(7):820-825. (Pubitemid 32762682)
37. VERMA S, RAJ RS, SHEWCHUK L, MATHER K, ANDERSON TJ: Cyclooxygenase-2 blockade does not impair endothelial vasodilators function in healthy volunteers. Randomised evaluation of reofecoxib versus naproxen on endothelium-dependent vasodilation. Circulation (2001) 104(24):2879-2882. (Pubitemid 33139096)
38. ROSS R: The pathogenesis of atherosclerosis: perspective for the 1990's. Nature (1993) 362(6423):801-809.
39. RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. (1997) 336(14):973-979. (Pubitemid 27152782)
40. BAKER CS, HALL RJ, EVANS TJ et al.: Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Atrerioscler. Thromb. Vasc. Biol. (1999) 19(3):646-655. (Pubitemid 29135167)
41. PRATICO D, CYRUS T, LI H, FITZGERALD GA: Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood (2000) 96(12):3823-3826.
42. CROFFORD LJ, OATES JC, MCCUNE WJ et al.: Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum. (2000) 43(8):1891-1896.
43. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286(8):954-959. (Pubitemid 33010342)
44. KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation (2001) 104(19):2280-2288. (Pubitemid 33049509)
45. VAN HECKEN A, SCHWARTZ JI, DEPRE M et al.: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. (2000) 40(10):1109-1120.
46. RAY WA, STEIN CM, HALL K, DAUGHERTY JR, GRIFFIN MR: Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 359(9301):118-123. (Pubitemid 34112540)
47. PATRONO C, COLLER B, DALEN J et al.: Platelet-active drugs. The relationships among dose, effectiveness, and side effects. Chest (2001) 119(1):39S-63S. (Pubitemid 32154194)
48. GARCIA RODRIGUEZ LA, VARAS C, PATRONO C: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology (2000) 11(4):382-387. (Pubitemid 30428929)
49. CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the anti-platelet effects of aspirin. N. Engl. J. Med. (2001) 345(25):1809-1817.
50. OUELLET M, RIENDEAU D, PERCIVAL MD: A high level of cyclooxygenase-2 inhibitor selectively is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. USA (2001) 98(25):14583-14588. (Pubitemid 33121435)